Tamoxifen is the gold standard for the adjuvant treatment of breast cancer in pre‐ and postmenopausal patients with estrogen receptor alpha (ERα)‐positive tumors and is the first selective estrogen receptor modulator [5, 6]. This evidence concerns the gene ESR1 and breast carcinoma.